The above findings suggest that low-dose IL-2 combined with rapamycin for the treatment of refractory SLE patients can increase the number of Treg, restore Th17/Treg balance, reduce disease activity and reduce the dose of prednison, which is beneficial for patients with refractory SLE. The gene discussed is IL2; the disease is systemic lupus erythematosus.